ARWR Arrowhead Pharmaceuticals (ARWR) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000879407
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
285
13F, latest reported quarter
What the filings say about ARWR
Insiders, 180 days
-$1.4M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.2M
2 notices
Arrowhead Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ARROWHEAD PHARMACEUTICALS, INC. insiders sold a net $1.4M of stock across 236 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Dec 5, 2025.
- The trade is 10.4% of the 111,459 shares held after it.
- 1 other insider sold within 30 days.
- 285 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director PERRY MICHAEL S sold about $1.0M of ARWR on Aug 18, 2026; 1 other insider sold within 30 days and 285 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Dec 19, 2025.
- The trade is 6.3% of the 31,600 shares held after it.
- 1 other insider sold within 30 days.
- 285 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director OLUKOTUN ADEOYE Y sold about $173.9K of ARWR on Aug 18, 2026; 1 other insider sold within 30 days and 285 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Apr 18, 2024.
- -5.9% median (-3.5% mean) 90-day return after 8 previous buys.
- The trade is 5.7% of the 52,012 shares held after it.
- 2 other insiders sold within 30 days.
- 285 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lu Hongbo sold about $228.3K of ARWR on May 12, 2026; 2 other insiders sold within 30 days and 285 funds added in the latest 13F quarter.Context
- 46 earlier Form 4 trades (code P or S) here by this insider (46 sales), the last on Mar 5, 2026.
- The trade is 4.4% of the 226,958 shares held after it.
- 2 other insiders sold within 30 days.
- 285 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Hamilton James C sold about $750.0K of ARWR on Apr 23, 2026; 2 other insiders sold within 30 days and 285 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 5.4% of the 162,905 shares held after it.
- 2 other insiders sold within 30 days.
- 285 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Apel Daniel Joseph sold about $627.9K of ARWR on Apr 22, 2026; 2 other insiders sold within 30 days and 285 funds added in the latest 13F quarter.236 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.4M over 180 days
-$1.2M over 90 days
below 66% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
285 funds bought in last quarter
more than 95% of Pharma & Biotech
Revenue
+23258.2% year over year
more than 99% of Pharma & Biotech
Margin
-0.2% net margin
more than 73% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
8.8% of the float short (float per yahoo 2026-10-26) · 4.0 days to cover · settled 2026-09-30
more than 62% of Pharma & Biotech
The situation: each line is one rule over one dataset
2 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ARWR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+56.7%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ARWR: institutional holders (13F)
13F holdings, latest reported quarter
14,830,553 sh
$1.2B
11,355,555 sh
$925.6M
8,039,804 sh
$655.3M
6,351,355 sh
$517.7M
6,110,953 sh
$498.1M
Congress trades in ARWR
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ARWR planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Michael Perry
Filed 2026-08-18
$1.0M
Adeoye Olukotun
Filed 2026-08-18
$173.9K
ARWR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Adaptiv Select ETF
$8.9M position · as of 2026-07-31
5.0%
Global X Genomics & Biotechnology ETF
$2.3M position · as of 2026-05-31
4.1%
First Trust NYSE Arca Biotechnology Index Fund
$95.0M position · as of 2026-06-30
3.4%
Alger Mid Cap 40 ETF
$4.2M position · as of 2026-06-30
2.7%
ALGER SMALL CAP FOCUS FUND
$23.0M position · as of 2026-07-31
2.7%
Invesco S&P Midcap 400 Pure Growth ETF
$8.5M position · as of 2026-07-31
2.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
50 registered trials, 12 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
13
Phase 1
2 active
17
Phase 2
2 active
8
Phase 3
4 active
1
Not applicable
0 active
11
Multi-phase
4 active
What changed recently
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
2026-10-14 · Completion moved 2026-09-30 → 2027-07
PHASE1,PHASE2
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
2026-10-10 · Active Not Recruiting → Completed
Phase 3
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
2026-10-09 · Active Not Recruiting → Completed
Phase 3
Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterole
2026-10-07 · Not Yet Recruiting → Recruiting
Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
2026-10-01 · Recruiting → Active Not Recruiting
Phase 3
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
2026-09-26 · Active Not Recruiting → Completed
Phase 3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Christopher Anzalone
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$9.0M
$42.6M
$2.1M
-20%
+46%
2024
$12.4M
-$5.4M
$3.5M
-69%
-6%
2023
$9.9M
-$2.2M
$3.2M
-38%
-51%
2022
$12.0M
-$40.1M
$4.1M
-23%
-33%
2021
$24.7M
$69.1M
$3.3M
+45%
+16%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.4M sold by insiders over 180 days, 285 funds added last quarter, $1.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ARWR financials
Revenue growth
+23258.2%
XBRL, annual
Net margin
-0.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$669.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ARWR
| FY Sep 2025 | $829.4M |
| FY Sep 2024 | $3.6M |
| FY Sep 2023 | $240.7M |
| FY Sep 2022 | $243.2M |
| FY Sep 2021 | $138.3M |
| Jun 2026 | $75.3M |
| Mar 2026 | $73.7M |
| Dec 2025 | $264.0M |
| Sep 2025 | $256.5M |
| Jun 2025 | $27.8M |
| Mar 2025 | $542.7M |
| Dec 2024 | $2.5M |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
-47.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ARWR
| FY Sep 2025 | -0.2% |
| FY Sep 2024 | -16,882% |
| FY Sep 2023 | -85.3% |
| FY Sep 2022 | -72.4% |
| FY Sep 2021 | -101.9% |
| Jun 2026 | -258.2% |
| Mar 2026 | -180.0% |
| Dec 2025 | +11.7% |
| Sep 2025 | -9.3% |
| Jun 2025 | -631.1% |
| Mar 2025 | +68.3% |
| Dec 2024 | -6,923% |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$75.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ARWR
| FY Sep 2025 | $156.9M |
| FY Sep 2024 | -$604.3M |
| FY Sep 2023 | -$330.6M |
| FY Sep 2022 | -$188.9M |
| FY Sep 2021 | $147.7M |
| Jun 2026 | -$181.3M |
| Mar 2026 | $81.9M |
| Dec 2025 | $11.3M |
| Sep 2025 | $13.0M |
| Jun 2025 | -$157.1M |
| Mar 2025 | $454.8M |
| Dec 2024 | -$153.8M |
| Sep 2024 | -$161.5M |
At each fiscal year end
Single quarter
Debt to equity
1.47x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity ARWR
| FY Sep 2025 | 0.00x |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | 1.47x |
| Mar 2026 | 1.11x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.09x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt ARWR
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | -0.09x |
| Mar 2026 | -0.05x |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-64.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ARWR
| FY Sep 2025 | -0.5% |
| FY Sep 2024 | -262.5% |
| FY Sep 2023 | -61.3% |
| FY Sep 2022 | -43.6% |
| FY Sep 2021 | -32.4% |
| Jun 2026 | -64.8% |
| Mar 2026 | -46.4% |
| Dec 2025 | +65.1% |
| Sep 2025 | -0.5% |
| Jun 2025 | -34.8% |
| Mar 2025 | -24.7% |
| Dec 2024 | -600.7% |
| Sep 2024 | -262.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-18.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ARWR
| FY Sep 2025 | -0.1% |
| FY Sep 2024 | -62.9% |
| FY Sep 2023 | -28.2% |
| FY Sep 2022 | -25.1% |
| FY Sep 2021 | -22.9% |
| Jun 2026 | -18.3% |
| Mar 2026 | -15.7% |
| Dec 2025 | +15.5% |
| Sep 2025 | -0.1% |
| Jun 2025 | -13.1% |
| Mar 2025 | -11.4% |
| Dec 2024 | -78.0% |
| Sep 2024 | -62.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital ARWR
| FY Sep 2025 | +24.1% |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | +123.4% |
| Sep 2025 | +24.1% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-15.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ARWR
| FY Sep 2025 | +8.8% |
| FY Sep 2024 | -70.9% |
| FY Sep 2023 | -33.8% |
| FY Sep 2022 | -32.0% |
| FY Sep 2021 | -28.5% |
| Jun 2026 | -15.0% |
| Mar 2026 | -13.3% |
| Dec 2025 | +27.6% |
| Sep 2025 | +8.8% |
| Jun 2025 | -10.9% |
| Mar 2025 | -10.6% |
| Dec 2024 | -84.4% |
| Sep 2024 | -70.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ARWR
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 43.39x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$8.9B
market value at close 2026-10-26 on 2026-07-30 shares, plus long-term debt only, 2026-06-30, minus cash 2024-06-30
Enterprise value ARWR
| FY Sep 2025 | $4.7B |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | $12.1B |
| Mar 2026 | $9.4B |
| Dec 2025 | $8.9B |
| Sep 2025 | $4.7B |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-0.9%
TTM free cash flow over market value at close 2026-10-26
FCF yield ARWR
| FY Sep 2025 | +3.3% |
| FY Sep 2024 | -25.1% |
| FY Sep 2023 | -11.5% |
| FY Sep 2022 | -5.4% |
| FY Sep 2021 | +2.3% |
| Jun 2026 | -0.7% |
| Mar 2026 | -0.6% |
| Dec 2025 | +3.6% |
| Sep 2025 | +3.3% |
| Jun 2025 | -0.8% |
| Mar 2025 | +0.6% |
| Dec 2024 | -24.4% |
| Sep 2024 | -25.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ARWR
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-09 | 2024-09 | 2023-09 | 2022-09 | |
|---|---|---|---|---|
| Revenue | $829.4M | $3.6M | $240.7M | $243.2M |
| Operating income | $98.3M | -$601.1M | -$205.0M | -$178.5M |
| Net income | -$1.6M | -$599.5M | -$205.3M | -$176.1M |
| EPS (diluted) | -0.01 | -5.00 | -1.92 | -1.67 |
| Operating cash flow | $179.6M | -$462.9M | -$153.9M | -$136.1M |
| Long-term debt | $0 | n/a | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-27
ARWR Stock Sonar score 6/7 axes
Find similar shapesCompareARWR ranks highest on growth (99th percentile) and institutional and government (95th), and lowest on insider conviction (16th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ARWR filings, in plain words
Are Arrowhead Pharmaceuticals insiders buying or selling ARWR?
In the 180 days to 2026-10-27, Arrowhead Pharmaceuticals insiders were net sellers, a net $1.4M across purchases and sales reported on Form 4, by 3 sellers.
Are there planned insider sales of ARWR?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $1.2M of stock; the latest, by Michael Perry, was filed 2026-08-18.
Read the full summary
In the 180 days to 2026-10-27, Arrowhead Pharmaceuticals insiders were net sellers of ARWR, a net $1.4M across purchases and sales reported on Form 4 by 3 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $1.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
